<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="32">
  <stage>Registered</stage>
  <submitdate>18/07/2005</submitdate>
  <approvaldate>18/07/2005</approvaldate>
  <actrnumber>ACTRN12605000017628</actrnumber>
  <trial_identification>
    <studytitle>Effect of Vitamin D Supplementation on Blood Pressure and Insulin Sensitivity</studytitle>
    <scientifictitle>A randomised phase III study to evaluate the effects of Vitamin D supplementation on patients with low vitamin D levels to reduce blood pressure levels and improve insulin sensitivity</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Blood Pressure</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Normal development and function of platelets and erythrocytes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A randomised double-blind clinical trial of 100 ug daily doses of vitamin D3 versus placebo tablets. </interventions>
    <comparator> Each participant will receive daily doses of vitamin D3 or placebo for 12 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood pressure</outcome>
      <timepoint>Measured at baseline and at 12 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Insulin sensitivity, as measured by a New Zealand developed index calculated from fasting blood levels of insulin and triglycerides.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Aged &gt;40 years (Tongan and Maori) and &gt;65 years (European) 25OHD levels &lt;50 nmol/L.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Treated diabetes, treated hypertension, taking of vitamin D supplements (including cod liver oil); serum calcium level above 2.60 mmol/L, regular outdoor activities during the middle of day during the study period, recent high sun exposure (eg. holidays in the Pacific islands); or planned holidays to areas with high sun exposure during the study period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisationb and packaging of tablets in non-identifiable packets that are used in consecutive order.</concealment>
    <sequence>Randomisation by computer software, no restriction</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Auckland</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Auckland</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert Scragg</name>
      <address>Epidemiology and Biostatistics
School of Population Health
University of Auckland
Tamaki Campus
Private Bag 92019
Auckland 1</address>
      <phone>+64 9 3737599 (Ext. 86336)</phone>
      <fax />
      <email>r.scragg@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Robert Scragg</name>
      <address>Epidemiology and Biostatistics
School of Population Health
Tamaki Campus
University of Auckland
Private Bag 92019
Auckland 1</address>
      <phone>+64 9 3737599 (Ext. 86336)</phone>
      <fax />
      <email>r.scragg@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>